Constellation Pharmaceuticals Inc

Constellation Pharmaceuticals is the first biopharmaceutical company dedicated to the development of novel therapeutics in the emerging field of Epigenetics, a new field of science which is focused on selective regulators of epigenetic function, which are critical to controlling gene expression.

CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today announced that Jigar Raythatha, CEO, will present a company overview at the J.P. Morgan Healthcare Conference at 10:50 AM EST on Thursday, January 14, 2021. A live audio webcast of the presentation and archive for replay will be available on the Investor Relations section of Constellation's website at  http://ir.constellationpharma.com/events-and-presentations/events . The audio webcast replay will be available for 30 days following the live presentation.

Constellation Pharmaceuticals to Present at J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Dec. 06, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today announced that two oral presentations and three posters relating to the Phase 2 MANIFEST and the Phase 3 MANIFEST-2 clinical trials of CPI-0610 in myelofibrosis (MF) were presented at the American Society of Hematology (ASH) Annual Meeting and Exposition. The preliminary data in these presentations are based on a data cutoff of September 29, 2020, and reflect an analysis of clinical activity in 63 first-line (1L) and 94 second-line (2L) or later patients.

Constellation Pharmaceuticals Provides Update of MANIFEST Study for CPI-0610 at ASH Meeting

CAMBRIDGE, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Constellation   Pharmaceuticals ,  Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, will host a virtual analyst/investor event and conference call on December 7 at 8:00 AM EDT to discuss the data from two oral presentations and two posters on the MANIFEST clinical trial for CPI-0610 being presented at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition.

Constellation Pharmaceuticals to Host Analyst / Investor Event to Discuss Update of MANIFEST Clinical Trial for CPI-0610 Presented at ASH Meeting

While the market driven by short-term sentiment influenced by the accomodative interest rate environment in the US, virus news and stimulus talks, many smart money investors are starting to get cautious towards the current bull run since March and hedging or reducing many of their long positions. Some fund managers are betting on Dow hitting 30,000 to generate strong returns. However, as we know, big investors usually buy stocks with strong fundamentals that can deliver gains both in bull and bear markets, which is why we believe we can profit from imitating them. In this article, we are going to take a look at the smart money sentiment surrounding Constellation Pharmaceuticals, Inc. (NASDAQ:CNST).

Was The Smart Money Wrong About Constellation Pharmaceuticals, Inc. (CNST)?

Constellation Pharmaceuticals, Inc. (CNST) CEO Jigar Raythatha on Q3 2020 Results - Earnings Call Transcript

CAMBRIDGE, Mass., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, will host a conference call at 8:00 AM EDT on October 29, 2020, to discuss its third quarter 2020 results and progress in its clinical programs. The event will be webcast live and can be accessed on the Investor Relations section of Constellation's website at http://ir.constellationpharma.com/events - and - presentations/events . To participate in the live question-and-answer session, please dial (877) 473-2077 (domestic) or (661) 378-9662 (international) and refer to conference ID 7374769.

Constellation Pharmaceuticals to Host Conference Call to Discuss Third Quarter 2020 Results

CAMBRIDGE, Mass., Sept.  09, 2020  (GLOBE NEWSWIRE) --  Constellation Pharmaceuticals , Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that the Company will participate in upcoming virtual investor conferences.  Jigar Raythatha, CEO, will present at:

Constellation Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences

Constellation Pharmaceuticals, Inc. (CNST) CEO Jigar Raythatha on Q2 2020 Results - Earnings Call Transcript

CAMBRIDGE, Mass., Aug.  05, 2020  (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced its second-quarter 2020 financial results. Constellation also announced its plans for a Phase 3 clinical trial of the BET inhibitor CPI-0610 following scientific advice and regulatory meetings with the U.S. Food and Drug Administration (FDA).

Constellation Pharmaceuticals Announces Second-Quarter 2020 Financial Results, Provides Regulatory Update

Constellation Pharmaceuticals (CNST) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Constellation Pharmaceuticals (CNST) Might Surprise This Earnings Season?

CAMBRIDGE, Mass., July  31, 2020  (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, will host a conference call at 8:00 AM EDT on August 5, 2020, to discuss its second quarter 2020 results and progress in its clinical programs. The event will be webcast live and can be accessed on the Investor Relations section of Constellation’s website at http://ir.constellationpharma.com/events - and - presentations/events . To participate in the live question-and-answer session, please dial (877) 473-2077 (domestic) or (661) 378-9662 (international) and refer to conference ID 4372778.

Constellation Pharmaceuticals to Host Conference Call to Discuss Second Quarter 2020 Results

CAMBRIDGE, Mass., June  16, 2020  (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., (Nasdaq: CNST) a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that it has priced an underwritten public offering of 5,500,000 shares of its common stock at a public offering price of $35.00 per share, for total gross proceeds of $192.5 million, before deducting underwriting discounts and commissions and expenses payable by Constellation. All of the shares in the offering are being sold by Constellation. In addition, Constellation has granted the underwriters a 30-day option to purchase up to 825,000 additional shares of its common stock at the public offering price, less the underwriting discount and commissions. The offering is expected to close on June 19, 2020, subject to customary closing conditions.

Constellation Pharmaceuticals Announces Pricing of Public Offering of Common Stock

CAMBRIDGE, Mass., June  15, 2020  (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., (Nasdaq: CNST) a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that it has commenced an underwritten public offering of 4,000,000 shares of its common stock. All of the shares are being offered by Constellation. In addition, Constellation expects to grant the underwriters a 30-day option to purchase up to an additional 600,000 shares of its common stock sold in the public offering.

Constellation Pharmaceuticals Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass., June  12, 2020  (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today announced that three posters relating to the MANIFEST clinical trial of CPI-0610 in myelofibrosis (MF) were published online in association with the European Hematology Association (EHA) annual meeting. The data in these posters are based on a data cutoff of April 17, 2020, and reflect an analysis of clinical activity in 51 first-line (1L) and 73 second-line (2L) patients. 

Constellation Pharmaceuticals Provides Updates of MANIFEST Study for CPI-0610 and EZH2 Franchise

CAMBRIDGE, Mass., June  10, 2020  (GLOBE NEWSWIRE) --  Constellation Pharmaceuticals , Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that the Company will participate in an upcoming virtual investor conference.  Jigar Raythatha, CEO, will present at the Goldman Sachs 41st Annual Global Healthcare Conference at 8:00 AM EDT on June 11.  A live audio webcast of Mr. Raythatha’s presentation and archives for replay will be available on the Investor Relations section of Constellation’s website at  http://ir.constellationpharma.com/events-and-presentations/events .  The audio webcast replay will be available for 30 days following the live presentation.

Constellation Pharmaceuticals to Participate in Investor Conference

CAMBRIDGE, Mass., June  08, 2020  (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that Jeffrey Humphrey, M.D., will join Constellation Pharmaceuticals as Chief Medical Officer.

Constellation Pharmaceuticals Announces Appointment of Dr. Jeffrey Humphrey as Chief Medical Officer

Constellation Pharmaceuticals, Inc. (CNST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Constellation Pharmaceuticals, Inc. (CNST) Upgraded to Buy: What Does It Mean for the Stock?

Constellation (CNST) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Is Constellation (CNST) Stock a Solid Choice Right Now?

Constellation Pharmaceuticals, Inc. (CNST) CEO Jigar Raythatha on Q1 2020 Results - Earnings Call Transcript

What Makes Constellation Pharmaceuticals, Inc. (CNST) a New Buy Stock

CAMBRIDGE, Mass., April  06, 2020  (GLOBE NEWSWIRE) --  Constellation Pharmaceuticals , Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that Richard Levy, M.D., has been appointed to its Board of Directors.

Constellation Pharmaceuticals Announces Appointment of Dr. Richard Levy to Board of Directors

Constellation Pharmaceuticals (CNST) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well

Why You Shouldn't Bet Against Constellation Pharmaceuticals (CNST) Stock

Constellation Pharmaceuticals, Inc. (CNST) CEO Jigar Raythatha on Q4 2019 Results - Earnings Call Transcript

News for Constellation Pharmaceuticals Inc Stock (CNST)